Office of Postsecondary Education

Type of Review: Revision.

Title: Fiscal Operations Report and Application to Participate in Federal Perkins Loan, Federal Supplemental Educational Opportunity Grant, and Federal Work-Study Programs.

Frequency: Annually.

Affected Public: Businesses or other for-profit; Non-for-profit institutions; State, local or Tribal Government, SEAs or LEAs.

Reporting and Recordkeeping Burden:

Responses: 1.

Burden Hours: 80,131.

Abstract: This application data will be used to compute the amount of funds needed by each institution during the 1997–98 Award Year. The Fiscal operations report data will be used to assess program effectiveness, account for funds expended during the 1995–96 Award Year, and as part of the institutional funding process.

[FR Doc. 96–70 Filed 1–16–96; 8:45 am]

BILLING CODE 4000–01–M

GENERAL SERVICES ADMINISTRATION

Public Building Service

Evo A. DeConcini Federal Building—United States Courthouse, City of Tucson, Arizona, Notice of Availability; Record of Decision

The United States General Services Administration (GSA) announces its decision, in accordance with the National Environmental Policy Act (NEPA) and the Regulations issued by the Council on Environmental Quality, December 8, 1995, to construct a new Federal building—United States Courthouse (FB–CT) in Tucson, Arizona.

The new FB–CT would consist of approximately 419,742 gross square feet (GSF) of building space and 187 on-site parking spaces. The project, designed to relieve overcrowded conditions at the existing court facilities in Tucson, is to be sited within the Central Business Area (CBA) of the City of Tucson, Arizona, is anticipated to be ready for occupancy in the year 1999. The agencies proposed to utilize the new FB–CT are currently housed within the existing Tucson FB–CT, located 55 E. Broadway, and in several leased, commercial, office buildings in the downtown Tucson area. An objective of this project is to consolidate these federal agencies into a single structure within the City's CBA.

Alternatives

The GSA has examined a range of alternatives that could feasibly attain the objectives of the proposed project. NEPA does not require that an agency consider every possibility, but requires that the range of alternatives be comprehensive so that the agency can make a ''reasoned choice'' among them. Alternatives examined were; 1) Granada North, 2) Granada South, 3) Central 4) Alameda and 5) No action. The Preferred site for the proposed project is Granada North. The site is bound by the US West bank/office building, the historic El Paso and Southwestern depot and courtyard, and a private paved parking lot on the west; West Congress Street on the north; Granada Avenue on the east; and the southern boundary would be a presently undetermined property line located approximately 600 feet south of West Congress Street.

Environmental Impacts/Mitigation Measures

The proposed construction of the FB–CT would result in several significant environmental impacts as described in the Draft Environmental Impact Statement (EIS). All practicable means to avoid or minimize impacts to the area are being considered to the development of the project. Mitigation measures were set forth in the Draft (EIS) and those that can be implemented were adopted by GSA. The GSA shall monitor the implementation of these mitigation measures necessary to assure that measures specified in the Draft and the Record of Decision are carried out.

The General Services Administration believes that there are no outstanding issues to be resolved with respect to the proposed project. The Record of Decision, prepared by GSA addressing this action, is on file and may be obtained from: Ms. Sheryll White, Asset Manager (9PT), U.S. General Services Administration, 525 Market Street, San Francisco, CA 94105 (415) 744–5076.

Dated: January 3, 1996.

Aki K. Nakao,

Acting Regional Administrator.

[FR Doc. 96–432 Filed 1–16–96; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director, Centers for Disease Control and Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Committee to the Director, CDC.

Timer and Date: 8:30 a.m.–3 p.m., January 26, 1996.

Place: CDC, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: This Committee advises the Director, CDC, on policy issues and broad strategies that will enable CDC, the Nation's prevention agency, to fulfill its mission of promoting health and quality of life by preventing and controlling disease, injury, and disability. The Committee recommends ways to incorporate prevention activities more fully into health care. It also provides guidance to help CDC work more effectively with its various constituents, in both the private and public sectors, to make prevention a practical reality.

Matters to be Discussed: The agenda will include updates from CDC Director, David Satcher, M.D., Ph.D., followed by committee discussion on the Report to Congress on CDC's Priorities for Chronic Disease Prevention and Environmental Health.

Agenda items are subject to change as priorities dictate.

The shutdown of the Federal Government prevented meeting the 15-day publication requirement.

Contact Person for More Information: Martha F. Katz, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE, Mailstop D–23, Atlanta, Georgia 30333, telephone 404/639–3243.

Dated: January 10, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–488 Filed 11–11–96; 4:57 pm]

BILLING CODE 4163–18–M

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines (ACCV) Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, and Subcommittee on Future Vaccines: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 8:30 a.m.–2:30 p.m., January 22, 1995. 8:30 a.m.–1 p.m., January 23, 1996.

Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW, Washington, DC 20007.

Status: Open to the public, limited only by the space available.

Purpose: The Committee shall advise and make recommendations tot he Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters to be Discussed: The Committee will receive an update on the National Vaccine Program Office and National Vaccine Advisory Committee operations; update on the Interagency Task Force on Vaccine Safety and funding for acting surveillance; update on immunization deliver: insights from recent research on vaccine coverage and a report on the new Women, Infants, and Childrens demonstration projects; update on vaccine program funding; update from the subcommittee on immunization coverage; proposal for a potential solution to the problem of an increasing menu of pediatric vaccines; defining a vaccine manufacturer/government partnership; update on adult immunization strategies and priorities; report on the influenza pandemic plan; role of the NVAC in fostering the pandemic influenza plan; update on the future vaccines subcommittee; presentation on the presence of reverse transcriptase activity in vaccine products; status of the Advisory Committee on Immunization Practices reevaluation of polio immunization recommendations and adolescent immunization; update on the injury compensation system; an update on USAID; and an information presentation on recent immunization compensation cases impacting immunization.

Name: Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines Subcommittee on Vaccine Safety.

Time and Date: 2:30 p.m.–5 p.m., January 22, 1996

Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW, Washington, DC 20007.

Status: Open to the public, limited only by the space available.

Purpose: This joint ACCV/NVAC subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters to be Discussed: The Subcommittee will discuss the Institute of Medicine vaccine safety forum and summary of planned workshops; the task force on safer childhood vaccines; and the charge of the Subcommittees.

Name: Subcommittee on Immunization Coverage.

Time and Date: 2:30 p.m.–5 p.m., January 22, 1996

Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW, Washington, DC 20007.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Immunization Coverage will identify strategies and policy options by which to further improve the levels of immunization coverage.

Matters to be Discussed: The Subcommittee will discuss determinants of under vaccination in preschool children; national, State, and local immunization coverage levels; current interventions for immunization and the future health environment.

Name: Subcommittee on Future Vaccines.

Time and Date: 2:30 p.m.–5 p.m., January 22, 1996.

Place: Savoy Suites Georgetown, 2505 Wisconsin Avenue, NW, Washington, DC 20007.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters to be Discussed: The Subcommittee will review and discuss the terms of reference for the Subcommittee; identify the matrix of interactions and partnerships, via specific case studies; describe the process of priority-setting by each of the members of the vaccine research and development community, and define barriers to new vaccine development.

Agenda items for each meeting are subject to change as priorities dictate.

The shutdown of the Federal Government prevented meeting the 15–day publication requirement.

Contact Person for More Information: Gloria A. Kovach, Committee Management Specialist, National Vaccine Program Office, CDC, 1600 Clifton Road, NE, M/S A20, Atlanta, Georgia 30333, telephon 404/639–3851.

Dated: January 10, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–487 Filed 1–11–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Circulatory System Devices Panel of the Medical Devices Advisory Committee

Date, time and place. January 29, 1996, 8:30 a.m., rm. 020B, 9200 Corporate Blvd, Rockville, MD. Attendees with a disability requiring special accommodations should contact Ed Rugenstein, Sociometrics, Inc., 301–608–2151.

Type of meeting and contact person. Open public hearing, January 29, 1996, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 1:30 p.m.; Ramiah Subramanian Center for Devices and Radiological Health (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8320, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, D.C. area), Circulatory System Devices Panel, code 12625.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data,